Fosamprenavir

CAS : 226700-79-4

Ref. 3D-FF178936

Informations sur le produit

• Nom: Fosamprenavir
• Synonymes: GW 433908, Carbamic acid, N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)-2-(phosphonooxy)propyl]-, C-[(3S)-tetrahydro-3-furanyl] ester, GW 433 908, Fosamprenavir, Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)-2-(phosphonooxy)propyl]-, C-[(3S)-tetrahydro-3-furanyl] ester, 226700-79-4, Amprenavir phosphate, ((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic Acid C-((3S)-Tetrahydro-3-furanyl) Ester, (3S)-Tetrahydrofuran-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](isobutyl)amino}-1-phenyl-3-(phosphonooxy)butan-2-yl]carbamate

Description

Fosamprenavir is a prodrug that is activated in the liver by esterases to amprenavir, its active form. Fosamprenavir inhibits HIV-1 protease, an enzyme that cleaves newly synthesized proteins into smaller peptides and prevents their maturation. It also binds to calcium ions and may inhibit the absorption of other drugs. Fosamprenavir has been shown to be effective in controlling HIV infection when used in combination with other antiretroviral drugs. However, it should not be used with sulfa drugs or benzalkonium chloride due to the risk of severe adverse effects on the kidneys and liver. Fosamprenavir has been shown to cause increased risk of hepatic impairment and should not be used in patients with impaired liver function. Fosamprenavir is metabolised into amprenavir which is excreted through urine as a glucuronide conjugate or through bile as

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 585.61 g/mol
• Formule: C₂₅H₃₆N₃O₉PS
• Degré de pureté: Min. 95%